Latest & greatest articles for obesity

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on obesity or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on obesity and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for obesity

21. A behavioural intervention for obese pregnant women did not reduce risk of diabetes

A behavioural intervention for obese pregnant women did not reduce risk of diabetes Signal - A behavioural intervention for obese pregnant women did not reduce risk of diabetes Dissemination Centre Discover Portal NIHR DC Discover A behavioural intervention for obese pregnant women did not reduce risk of diabetes Published on 4 November 2015 This large NIHR-funded UK trial found that a behavioural intervention for obese pregnant women did not reduce their risk of developing diabetes during (...) of the intervention. The trial result does emphasise the need to follow NICE recommendations to test for diabetes in all pregnant women with obesity. Share your views on the research. Why was this study needed? Obesity rates in UK women have risen between 1993 and 2011 from 16% to 26%. Rates of gestational diabetes are also increasing. Women who are obese when they become pregnant have a higher risk of developing diabetes, high blood pressure, or having babies that are on average larger than the duration

NIHR Dissemination Centre2018

22. Prophylactic incisional negative pressure wound therapy reduces the risk of surgical site infection after caesarean section in obese women: a pragmatic randomised clinical trial

Prophylactic incisional negative pressure wound therapy reduces the risk of surgical site infection after caesarean section in obese women: a pragmatic randomised clinical trial 30066454 2018 09 08 1471-0528 2018 Aug 01 BJOG : an international journal of obstetrics and gynaecology BJOG Prophylactic incisional negative pressure wound therapy reduces the risk of surgical site infection after caesarean section in obese women: a pragmatic randomised clinical trial. 10.1111/1471-0528.15413 (...) To evaluate the reduction of surgical site infections by prophylactic incisional negative pressure wound therapy compared with standard postoperative dressings in obese women giving birth by caesarean section. Multicentre randomised controlled trial. Five hospitals in Denmark. Obese women (prepregnancy body mass index (BMI) ≥30 kg/m 2 ) undergoing elective or emergency caesarean section. The participants were randomly assigned to incisional negative pressure wound therapy or a standard dressing after

EvidenceUpdates2018

23. Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials

Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials 30206335 2018 09 12 1476-5497 2018 Sep 11 International journal of obesity (2005) Int J Obes (Lond) Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials. 10.1038/s41366-018-0204-0 (...) Intermittent dieting may be an alternative to continuous dieting for weight reduction. To evaluate the effect of intermittent dieting versus continuous dieting on weight and body composition in overweight or obese adults. A systematic review and meta-analysis of randomized controlled trials (RCTs). Five databases were searched until February 2018 for RCTs comparing intermittent versus continuous dieting. Intermittent dieting consisted of two types: regular intermittent was caloric restriction interspersed

EvidenceUpdates2018

24. Prenatal education of overweight or obese pregnant women to prevent childhood overweight (the ETOIG study): an open-label, randomized controlled trial

Prenatal education of overweight or obese pregnant women to prevent childhood overweight (the ETOIG study): an open-label, randomized controlled trial 30242235 2018 09 22 1476-5497 2018 Sep 21 International journal of obesity (2005) Int J Obes (Lond) Prenatal education of overweight or obese pregnant women to prevent childhood overweight (the ETOIG study): an open-label, randomized controlled trial. 10.1038/s41366-018-0205-z We aimed to evaluate whether pre and perinatal education of pregnant (...) and nutritional counseling program for overweight women, starting after 3 months of gestation, did not significantly change post-natal excessive weight gain of infants or prevent overweight in mothers and children 2 years after delivery. Parat Sophie S AP-HP, Department of Medecine and Neonatal Reanimation, Hôpital Cochin-Port Royal, Paris, France. sophie.parat@aphp.fr. Nègre Véronique V RePPOP-Franche Comte Network for Pediatric Obesity, Obesity Specialized Center CHU Nice, Paris, France. Baptiste Amandine

EvidenceUpdates2018

25. Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity

Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity 30185920 2018 09 22 1476-5497 2018 Sep 05 International journal of obesity (2005) Int J Obes (Lond) Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity. 10.1038/s41366-018-0122-1 Functional Imagery Training (FIT

EvidenceUpdates2018

26. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Overweight and obesity have been associated with adverse health effects. Objective: To systematically review evidence on benefits and harms of behavioral and pharmacotherapy weight loss and weight loss maintenance interventions in adults to inform the US Preventive Services Task (...) ) focusing on weight loss or weight loss maintenance in adults. Data Extraction and Synthesis: Data were abstracted by one reviewer and confirmed by another. Random-effects meta-analyses were conducted for weight loss outcomes in behavior-based interventions. Main Outcomes and Measures: Health outcomes, weight loss or weight loss maintenance, reduction in obesity-related conditions, and adverse events. Results: A total of 122 RCTs (N = 62 533) and 2 observational studies (N = 209 993) were identified

JAMA2018

27. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement.

Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. Importance: More than 35% of men and 40% of women in the United States are obese. Obesity is associated with health problems such as increased risk for coronary heart disease, type 2 diabetes, various types of cancer, gallstones, and disability. Obesity is also associated with an increased risk for death, particularly among adults younger (...) than 65 years. Objective: To update the US Preventive Services Task Force (USPSTF) 2012 recommendation on screening for obesity in adults. Evidence Review: The USPSTF reviewed the evidence on interventions (behavioral and pharmacotherapy) for weight loss or weight loss maintenance that can be provided in or referred from a primary care setting. Surgical weight loss interventions and nonsurgical weight loss devices (eg, gastric balloons) are considered to be outside the scope of the primary

JAMA2018

28. Prophylactic Negative Pressure Wound Therapy and Wound Complication After Cesarean Delivery in Women With Class II or III Obesity: A Randomized Controlled Trial

Prophylactic Negative Pressure Wound Therapy and Wound Complication After Cesarean Delivery in Women With Class II or III Obesity: A Randomized Controlled Trial 29995726 2018 07 25 1873-233X 132 2 2018 Aug Obstetrics and gynecology Obstet Gynecol Prophylactic Negative Pressure Wound Therapy and Wound Complication After Cesarean Delivery in Women With Class II or III Obesity: A Randomized Controlled Trial. 377-384 10.1097/AOG.0000000000002744 To compare the occurrence of superficial surgical (...) site infections in obese women using prophylactic negative pressure therapy with standard dressings after cesarean delivery. We conducted a randomized controlled, nonblinded, two-center study of prophylactic negative pressure therapy compared with standard surgical dressings placed at the time of primary closure at cesarean delivery in obese women with body mass indexes (BMI) of 35 or higher (ie, class II and III obesity). Our primary outcome was occurrence of a superficial surgical site infection

EvidenceUpdates2018

29. Is four-week underwater treadmill exercise regimen compared to home exercise efficacious for pain relief and functional improvement in obese patients with knee osteoarthritis? A randomized controlled trial

Is four-week underwater treadmill exercise regimen compared to home exercise efficacious for pain relief and functional improvement in obese patients with knee osteoarthritis? A randomized controlled trial 30064262 2018 08 01 1477-0873 2018 Aug 01 Clinical rehabilitation Clin Rehabil Is four-week underwater treadmill exercise regimen compared to home exercise efficacious for pain relief and functional improvement in obese patients with knee osteoarthritis? A randomized controlled trial (...) . 269215518792041 10.1177/0269215518792041 To investigate the efficacy of a four-week underwater treadmill exercise regimen compared to a home exercise regimen relative to pain relief and functional improvement in obese patients with knee osteoarthritis. Single-blind randomized controlled trial. Outpatient. Eighty primary knee osteoarthritis with pain ⩾5/10 and body mass index ⩾25 kg/m 2 . Daily quadriceps exercise at home for 30 minutes (control group) or underwater treadmill exercise (study group) for 30

EvidenceUpdates2018

30. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. Background Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. Methods We randomly assigned 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to receive either lorcaserin (10 mg twice daily (...) the lorcaserin group (13 vs. 4, P=0.04). Conclusions In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).

NEJM2018

31. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss. METHODS

Lancet2018

32. Giving obese pregnant women metformin had no effect on baby’s weight at birth

Giving obese pregnant women metformin had no effect on baby’s weight at birth Signal - Giving obese pregnant women metformin had no effect on baby’s weight at birth Dissemination Centre Discover Portal NIHR DC Discover Giving obese pregnant women metformin had no effect on baby’s weight at birth Published on 15 September 2015 A large trial found that giving obese pregnant women the diabetes drug, metformin, to prevent heavier babies, had no effect compared with an inactive dummy tablet (...) of a mother’s pregnancy to a baby’s birth. The researchers now aim to track the children’s weight and health beyond birth to see if there are any other long-term benefits or side-effects. For now, the results show metformin does not work for this purpose. Share your views on the research. Why was this study needed? Almost a quarter of women (24%) were obese in 2013 in England. This is up from 16% 20 years earlier. Obese pregnant women are more likely than other women to give birth to heavier babies

NIHR Dissemination Centre2018

33. Perioperative Management of Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome: A Workshop Report

Perioperative Management of Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome: A Workshop Report

American Thoracic Society2018

35. Obesity

Obesity Top results for obesity - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for obesity The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

36. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.

Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. BACKGROUND: There has been considerable interest in providing antenatal dietary and lifestyle advice for women with obesity or who are overweight during pregnancy, as a strategy to limit gestational weight gain and improve maternal and infant health. However, such antenatal interventions appear to have a modest effect on gestational weight gain and other clinical pregnancy and birth (...) women with obesity or who are overweight, acting to reduce glucose production in the liver and improve glucose uptake in smooth muscle cells, and therefore improve the overall metabolic health of women in pregnancy and reduce the risk of known adverse pregnancy outcomes. OBJECTIVES: To evaluate the role of metformin in pregnant women with obesity or who are overweight, on maternal and infant outcomes, including adverse effects of treatment and costs. SEARCH METHODS: We searched Cochrane Pregnancy

Cochrane2018

37. Association between maternal adherence to healthy lifestyle practices and risk of obesity in offspring: results from two prospective cohort studies of mother-child pairs in the United States.

Association between maternal adherence to healthy lifestyle practices and risk of obesity in offspring: results from two prospective cohort studies of mother-child pairs in the United States. OBJECTIVE: To examine the association between an overall maternal healthy lifestyle (characterized by a healthy body mass index, high quality diet, regular exercise, no smoking, and light to moderate alcohol intake) and the risk of developing obesity in offspring. DESIGN: Prospective cohort studies (...) of mother-child pairs. SETTING: Nurses' Health Study II (NHSII) and Growing Up Today Study (GUTS) in the United States. PARTICIPANTS: 24 289 GUTS participants aged 9-14 years at baseline who were free of obesity and born to 16 945 NHSII women. MAIN OUTCOME MEASURE: Obesity in childhood and adolescence, defined by age and sex specific cutoff points from the International Obesity Task Force. Risk of offspring obesity was evaluated by multivariable log-binomial regression models with generalized estimating

BMJ2018

38. Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study

Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study 29777228 2018 06 26 1476-5497 42 5 2018 Jun International journal of obesity (2005) Int J Obes (Lond) Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. 953-963 10.1038/s41366-018-0105-2 Obesity causes secondary hypogonadism (HG) in men. Standard testosterone (T) replacement therapy improves (...) metabolic parameters but leads to infertility. To evaluate clomiphene citrate (CC) treatment of adult men with male obesity-associated secondary hypogonadism (MOSH). Single-center, randomized, double-blind, placebo-controlled trial. Seventy-eight men aged 36.5 ± 7.8 years with a body mass index (BMI) > 30 kg/m 2 , total testosterone (TT) ≤ 300 ng/dL, and symptoms in the ADAM questionnaire. Random allocation to receive 50 mg CC or placebo (PLB) for 12 weeks. (1) Clinical features: ADAM and sexual

EvidenceUpdates2018

39. Obesity

Obesity Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

Trip Evidence Maps2018

40. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. BACKGROUND: Weight loss is often key in the management of obese or overweight patients with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like peptide-1 (...) between treatment groups (22 [88%] of 25 in the MEDI0382 group vs 23 [88%] of 26 in the placebo group); gastrointestinal disorders (18 [72%] vs 13 [40%]) and decreased appetite (five [20%] vs none) occurred more frequently with MEDI0382 than placebo. No participants in the MEDI0382 group had a grade 3 or worse TEAE (vs two [8%] in the placebo group). INTERPRETATION: MEDI0382 has the potential to deliver clinically meaningful reductions in blood glucose and bodyweight in obese or overweight individuals

Lancet2018